Clinical Genomics segmentation is organized around four principal applications: diagnostic testing, prenatal screening, oncology profiling, and rare‑disease investigation. Diagnostic testing, which includes somatic mutation panels and hereditary‑cancer assays, represents the dominant revenue driver (≈45 %) because reimbursement frameworks and clinical guidelines mandate comprehensive, validated pipelines. Prenatal screening (≈20 %) relies on non‑invasive fetal DNA analysis and demands rapid turn‑around, driving growth in targeted‑panel and low‑coverage whole‑genome solutions. Oncology profiling (≈25 %) integrates tumor sequencing with companion‑diagnostic reporting, pushing demand for whole‑exome and transcriptomic workflows that support biomarker‑driven therapy selection. Rare‑disease investigation (≈10 %) leverages whole‑genome sequencing to resolve phenotypic heterogeneity, contributing a high‑margin niche. Type‑level segmentation distinguishes targeted panels, whole‑exome sequencing (WES), whole‑genome sequencing (WGS), transcriptomics, and epigenomics. Targeted panels dominate diagnostics due to cost efficiency, while WES and WGS command larger shares in oncology and rare‑disease applications because of their breadth of coverage. Transcriptomics and epigenomics, though smaller in absolute terms, add analytical depth that enhances variant interpretation across all applications. This market taxonomy demonstrates how each application‑type pairing shapes the overall Clinical Genomics market size.
